Business Description
EyePoint Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US30233G1004
Description
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 12.03 | |||||
| Equity-to-Asset | 0.7 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.27 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -0.66 | |||||
| Beneish M-Score | -2.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -23.9 | |||||
| 3-Year EBITDA Growth Rate | 13.8 | |||||
| 3-Year EPS without NRI Growth Rate | 19.7 | |||||
| 3-Year FCF Growth Rate | 67.1 | |||||
| 3-Year Book Growth Rate | 74.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -25.48 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | -57.71 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 22.85 | |||||
| 9-Day RSI | 34.35 | |||||
| 14-Day RSI | 39.86 | |||||
| 6-1 Month Momentum % | -58.67 | |||||
| 12-1 Month Momentum % | 1.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.75 | |||||
| Quick Ratio | 4.69 | |||||
| Cash Ratio | 4.51 | |||||
| Days Inventory | 346.13 | |||||
| Days Sales Outstanding | 24.09 | |||||
| Days Payable | 806.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -39.3 | |||||
| Shareholder Yield % | 5.84 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 91.35 | |||||
| Operating Margin % | -195.71 | |||||
| Net Margin % | -172.3 | |||||
| FCF Margin % | -186.91 | |||||
| ROE % | -50.45 | |||||
| ROA % | -32.29 | |||||
| ROIC % | -160.76 | |||||
| 3-Year ROIIC % | -164.53 | |||||
| ROC (Joel Greenblatt) % | -629.38 | |||||
| ROCE % | -42.37 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 7.09 | |||||
| PB Ratio | 1.83 | |||||
| Price-to-Tangible-Book | 1.83 | |||||
| EV-to-EBIT | -1.97 | |||||
| EV-to-EBITDA | -1.99 | |||||
| EV-to-Revenue | 3.39 | |||||
| EV-to-Forward-Revenue | 7.16 | |||||
| EV-to-FCF | -1.81 | |||||
| Price-to-Median-PS-Value | 0.84 | |||||
| Price-to-Net-Current-Asset-Value | 2.09 | |||||
| Price-to-Net-Cash | 2.26 | |||||
| Earnings Yield (Greenblatt) % | -50.76 | |||||
| FCF Yield % | -22.07 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
EyePoint Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 46.661 | ||
| EPS (TTM) (€) | -1.647 | ||
| Beta | 3.5 | ||
| Volatility % | 282.06 | ||
| 14-Day RSI | 39.86 | ||
| 14-Day ATR (€) | 0.214547 | ||
| 20-Day SMA (€) | 7.4837 | ||
| 12-1 Month Momentum % | 1.45 | ||
| 52-Week Range (€) | 5.4 - 27.6 | ||
| Shares Outstanding (Mil) | 53.52 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
EyePoint Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
EyePoint Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
EyePoint Pharmaceuticals Inc Frequently Asked Questions
What is EyePoint Pharmaceuticals Inc(STU:PV3B)'s stock price today?
The current price of STU:PV3B is €7.01. The 52 week high of STU:PV3B is €27.60 and 52 week low is €5.40.
When is next earnings date of EyePoint Pharmaceuticals Inc(STU:PV3B)?
The next earnings date of EyePoint Pharmaceuticals Inc(STU:PV3B) is 2024-11-01 Est..
Does EyePoint Pharmaceuticals Inc(STU:PV3B) pay dividends? If so, how much?
EyePoint Pharmaceuticals Inc(STU:PV3B) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers